Friday, July 15, 2016

Rewarding, I'll bet

Before I forget, a nice profile of Salvatore DiRosa, an Italian medicinal chemist in last week's C&EN (article by Andrea Widener), including finding a position after a site closure: 
2013: Surviving a company’s demise
 La Rosa had been at Siena [CJ's note: Siena Biotech, in Tuscany] for nine years when the company, which was owned by a bank, fell victim to the recent global financial crisis. “I was still there, but I knew what was happening. It was one of those situations where you say, ‘What am I doing here? I’m waiting for this situation to collapse.’ ” 
Today: Finding cures for children’s tumors
A former colleague offered La Rosa a job in New York City at the nonprofit Children’s Tumor Foundation, which supports research into neurofibromatosis, a benign tumor that can be debilitating. Now La Rosa is vice president for R&D. Working with patients and doctors is completely different from working in industry, he says. And he loves it. “There is a really strong drive to do something that is useful for patients today.”
Italian biotech companies can be owned by banks? Huh. 


  1. CJ-About your comment, "Italian biotech companies can be owned by banks?" Yea why not if Mafioso can own the bankbank?

  2. I searched your site for "site closing" and found this interesting list in the commments of a 2010 site closing post. How many more have been added to the list over the past 6 years??

    "Number of large US pharmaceutical R&D sites shuttered in past 15 years – Syntex, Searle, Sterling, UpJohn, Park-Davis, Bayer, Berlex, Alza, JNJ – Ortho, Monsanto pharma, Dupont pharma, P&G pharma, Glaxo – RTP (plus 4 R&D sites around the world), Robins, Knoll (BASF), 3M pharma, Ciba Summit, Burroughs-Wellcome, Rorer, Merrill-Dow, Rhone-Poulenc, Sanofi-Aventis, Wyeth (6 sites), Lederle, Pfizer – New London, AstraZeneca – Delaware (multiple sites in the EU), Schering Plough – Union site, Merck (ex-US Merck Frosst and Organon plus multiple other EU sites)"